IPSEN (IPN.PA) Stock Fundamental Analysis
Europe - EPA:IPN - FR0010259150 - Common Stock
114.2 EUR
-1.2 (-1.04%)
Taking everything into account, IPN scores 6 out of 10 in our fundamental rating. IPN was compared to 49 industry peers in the Pharmaceuticals industry. IPN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IPN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IPN was profitable.
IPN had a positive operating cash flow in the past year.
IPN had positive earnings in each of the past 5 years.
In the past 5 years IPN always reported a positive cash flow from operatings.
1.2 Ratios
IPN has a Return On Assets (6.56%) which is in line with its industry peers.
IPN has a Return On Equity of 10.59%. This is comparable to the rest of the industry: IPN outperforms 51.02% of its industry peers.
IPN's Return On Invested Capital of 14.88% is fine compared to the rest of the industry. IPN outperforms 77.55% of its industry peers.
IPN had an Average Return On Invested Capital over the past 3 years of 12.97%. This is below the industry average of 15.25%.
The 3 year average ROIC (12.97%) for IPN is below the current ROIC(14.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| ROIC | 14.88% |
ROA(3y)9.04%
ROA(5y)10.56%
ROE(3y)14.84%
ROE(5y)18.77%
ROIC(3y)12.97%
ROIC(5y)15.34%
1.3 Margins
IPN has a Profit Margin (11.91%) which is in line with its industry peers.
IPN's Profit Margin has declined in the last couple of years.
IPN's Operating Margin of 26.01% is fine compared to the rest of the industry. IPN outperforms 71.43% of its industry peers.
IPN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 83.32%, IPN belongs to the top of the industry, outperforming 87.76% of the companies in the same industry.
IPN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.01% | ||
| PM (TTM) | 11.91% | ||
| GM | 83.32% |
OM growth 3Y-13.94%
OM growth 5Y-4.28%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IPN is creating value.
IPN has more shares outstanding than it did 1 year ago.
IPN has about the same amout of shares outstanding than it did 5 years ago.
IPN has a better debt/assets ratio than last year.
2.2 Solvency
IPN has an Altman-Z score of 4.36. This indicates that IPN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.36, IPN is in the better half of the industry, outperforming 69.39% of the companies in the same industry.
IPN has a debt to FCF ratio of 1.69. This is a very positive value and a sign of high solvency as it would only need 1.69 years to pay back of all of its debts.
IPN has a Debt to FCF ratio of 1.69. This is amongst the best in the industry. IPN outperforms 89.80% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that IPN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.20, IPN is in the better half of the industry, outperforming 75.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | 4.36 |
ROIC/WACC1.96
WACC7.6%
2.3 Liquidity
IPN has a Current Ratio of 1.98. This is a normal value and indicates that IPN is financially healthy and should not expect problems in meeting its short term obligations.
IPN's Current ratio of 1.98 is fine compared to the rest of the industry. IPN outperforms 73.47% of its industry peers.
A Quick Ratio of 1.80 indicates that IPN should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.80, IPN belongs to the top of the industry, outperforming 83.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.24% over the past year.
Measured over the past years, IPN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.79% on average per year.
IPN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.45%.
The Revenue has been growing slightly by 5.83% on average over the past years.
EPS 1Y (TTM)12.24%
EPS 3Y4.15%
EPS 5Y8.79%
EPS Q2Q%44.4%
Revenue 1Y (TTM)9.45%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%9.67%
3.2 Future
IPN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.16% yearly.
Based on estimates for the next years, IPN will show a small growth in Revenue. The Revenue will grow by 4.89% on average per year.
EPS Next Y1.38%
EPS Next 2Y3.24%
EPS Next 3Y4.35%
EPS Next 5Y5.16%
Revenue Next Year6.84%
Revenue Next 2Y5.78%
Revenue Next 3Y6.17%
Revenue Next 5Y4.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.12 indicates a reasonable valuation of IPN.
IPN's Price/Earnings ratio is a bit cheaper when compared to the industry. IPN is cheaper than 75.51% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.20, IPN is valued rather cheaply.
With a Price/Forward Earnings ratio of 10.43, the valuation of IPN can be described as very reasonable.
IPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IPN is cheaper than 75.51% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.70. IPN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.12 | ||
| Fwd PE | 10.43 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IPN indicates a rather cheap valuation: IPN is cheaper than 95.92% of the companies listed in the same industry.
63.27% of the companies in the same industry are more expensive than IPN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.56 | ||
| EV/EBITDA | 5.42 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IPN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)8.04
PEG (5Y)1.27
EPS Next 2Y3.24%
EPS Next 3Y4.35%
5. Dividend
5.1 Amount
IPN has a Yearly Dividend Yield of 1.17%.
IPN's Dividend Yield is comparable with the industry average which is at 3.04.
With a Dividend Yield of 1.17, IPN pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.17% |
5.2 History
The dividend of IPN has a limited annual growth rate of 3.72%.
Dividend Growth(5Y)3.72%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
IPN pays out 25.90% of its income as dividend. This is a sustainable payout ratio.
IPN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.9%
EPS Next 2Y3.24%
EPS Next 3Y4.35%
EPA:IPN (9/18/2025, 5:36:15 PM)
114.2
-1.2 (-1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.53%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap9.57B
Analysts70
Price Target128.52 (12.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.17% |
Yearly Dividend1.2
Dividend Growth(5Y)3.72%
DP25.9%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.4%
PT rev (3m)0.87%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.39%
EPS NY rev (3m)-0.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.12 | ||
| Fwd PE | 10.43 | ||
| P/S | 2.55 | ||
| P/FCF | 18.56 | ||
| P/OCF | 10.67 | ||
| P/B | 2.26 | ||
| P/tB | 7.17 | ||
| EV/EBITDA | 5.42 |
EPS(TTM)10.27
EY8.99%
EPS(NY)10.95
Fwd EY9.58%
FCF(TTM)6.15
FCFY5.39%
OCF(TTM)10.71
OCFY9.37%
SpS44.86
BVpS50.46
TBVpS15.93
PEG (NY)8.04
PEG (5Y)1.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| ROCE | 18.07% | ||
| ROIC | 14.88% | ||
| ROICexc | 20.46% | ||
| ROICexgc | 77.25% | ||
| OM | 26.01% | ||
| PM (TTM) | 11.91% | ||
| GM | 83.32% | ||
| FCFM | 13.72% |
ROA(3y)9.04%
ROA(5y)10.56%
ROE(3y)14.84%
ROE(5y)18.77%
ROIC(3y)12.97%
ROIC(5y)15.34%
ROICexc(3y)20.33%
ROICexc(5y)25.52%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)15.75%
ROCE(5y)18.64%
ROICexcg growth 3Y-59.92%
ROICexcg growth 5Y-22.83%
ROICexc growth 3Y-29.05%
ROICexc growth 5Y-11.89%
OM growth 3Y-13.94%
OM growth 5Y-4.28%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 0.5 | ||
| Cap/Depr | 55.54% | ||
| Cap/Sales | 10.15% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 53.9% | ||
| Profit Quality | 115.14% | ||
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 4.36 |
F-Score7
WACC7.6%
ROIC/WACC1.96
Cap/Depr(3y)131.36%
Cap/Depr(5y)124.73%
Cap/Sales(3y)11.81%
Cap/Sales(5y)11.18%
Profit Quality(3y)85.87%
Profit Quality(5y)89.99%
High Growth Momentum
Growth
EPS 1Y (TTM)12.24%
EPS 3Y4.15%
EPS 5Y8.79%
EPS Q2Q%44.4%
EPS Next Y1.38%
EPS Next 2Y3.24%
EPS Next 3Y4.35%
EPS Next 5Y5.16%
Revenue 1Y (TTM)9.45%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%9.67%
Revenue Next Year6.84%
Revenue Next 2Y5.78%
Revenue Next 3Y6.17%
Revenue Next 5Y4.89%
EBIT growth 1Y66.72%
EBIT growth 3Y-6.06%
EBIT growth 5Y1.3%
EBIT Next Year27.18%
EBIT Next 3Y13.1%
EBIT Next 5Y7.52%
FCF growth 1Y-33.64%
FCF growth 3Y-35.67%
FCF growth 5Y-17.46%
OCF growth 1Y-8.92%
OCF growth 3Y-0.07%
OCF growth 5Y7.84%